© 2025 HSP News Service, L.L.C.
Artificial intelligence (AI) could improve screening for cervical cancer, enhancing accuracy and efficiency, according to a recent review article published by Wu et al in Cancer Biology & Medicine. The report, authored by a team of researchers from the Chinese Academy of Medical Sciences and...
As reported in the Journal of Clinical Oncology by Matei et al, the final overall survival analysis in the long-term follow-up of the phase III NRG258 trial has shown no difference between adjuvant chemoradiation (C-RT) vs chemotherapy (CT) in patients with locally advanced endometrial carcinoma....
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study published by Huang et al in Nature. The findings could improve the accuracy of genetic testing and allow health-care professionals to offer more precise risk assessments and...
As reported in the Journal of Clinical Oncology by Scambia et al, the final overall survival results of the phase III SOLO3 trial showed similar outcomes with olaparib vs non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer. In the initial report...
A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is published in Nature Medicine. “Ovarian tumors are common and are often detected by chance,” said...
In an Italian phase III trial (HORSE; MITO-18) reported in Journal of Clinical Oncology, Fagotti et al found that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery without neoadjuvant chemotherapy did not improve progression-free survival vs no...
The results of the HARMOny study published in JACC: CardioOncology by Beekman et al did not reveal a long-term adverse effect of prophylactic surgical menopause on the development of coronary artery calcium—a marker of cardiovascular disease risk—in women with a high familial risk of ovarian...
Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...
As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study showed no significant differences in progression-free or overall survival with first-line lenvatinib/pembrolizumab vs chemotherapy in patients with...
Over the past year, several important studies in ovarian cancer have been presented at multiple oncology meetings and published in a number of peer-reviewed publications. In this installment of a two-part discussion for The ASCO Post Newsreels, Ursula A. Matulonis, MD, and Joyce F. Liu, MD, MPH, discuss antibody-drug conjugates and clinical trials including PRIMA and ATHENA. In part two of this feature, Dr. Matulonis and Dr. Liu talk about low-grade serous ovarian carcinoma and an important recently published study. Filmed November 22, 2024
The final overall survival analysis of the phase III PRIMA trial found no survival benefit for maintenance niraparib over placebo in advanced ovarian cancer. However, the PARP inhibitor continued to exert a sustained progression-free survival benefit, investigators reported at the European Society...
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...
Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology Jean-Marc Classe, MD, PhD, Head of the Oncological Surgery Department at the Institut de Cancérologie de l’Ouest, Saint Herblain, France, and colleagues, the addition of hyperthermic...
The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology, which highlighted international collaborations to improve cancer therapy and outcomes across China and Asia....
Just 50% of patients with early-onset cancers may report discussing fertility preservation options with their physicians prior to receiving oncology treatments, according to a recent study published by Keller et al in JAMA Network Open. Background “From an early-onset cancer diagnosis through to...
Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post...
In a study reported in a research letter in JAMA Network Open, Bercow et al found reduced use of primary cytoreductive surgery (PCS) and increased use of neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) in patients with advanced epithelial ovarian cancer during...
In interim analyses of a Chinese phase III trial (COMPASSION-16) reported in The Lancet, Wu et al found that the addition of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, to platinum-based chemotherapy with or without bevacizumab significantly improved progression-free and overall...
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer. Study Details In the open-label trial,...
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma. Study Details In the multicenter trial, 37 evaluable patients with exposure...
Canadian vaccination programs may switch to a one-dose, gender-neutral human papillomavirus (HPV) vaccination approach to eliminate cervical cancer, according to a recent study published by Drolet et al in the Canadian Medical Association Journal. Background HPV is known to cause cervical cancer...
In an analysis from the phase III SHAPE trial reported in the Journal of Clinical Oncology, Ferguson et al found that simple hysterectomy was associated with a reduced risk of sexual dysfunction vs radical hysterectomy in patients with low-risk, early-stage cervical cancer. The trial showed...
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...
As reported in The Lancet by Lorusso et al, overall survival results from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial indicated a significant benefit of pembrolizumab vs placebo with concurrent chemoradiotherapy followed by pembrolizumab vs placebo in patients with newly diagnosed,...
In the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at the European Society for Medical Oncology (ESMO) Congress 2024, the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pembrolizumab continued as monotherapy, improved overall survival in previously untreated, high-risk...
On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.1 Tisotumab vedotin is a tissue factor–directed antibody and microtubule inhibitor conjugate. The agent was granted...
Researchers have identified thousands of genetic changes in a gene that may increase the risk of developing breast and ovarian cancers, according to a recent study published by Olvera-León et al in Cell. The findings may pave the way for better risk assessment and more personalized care. ...
A study by Hutchinson et al quantifying the socioeconomic burden of ovarian cancer in 11 countries, including the United States, estimates that nearly $70 billion in socioeconomic losses may be attributable to ovarian cancer. Moreover, health expenditures to cover treatment in the first 2 years...
The novel antibody-drug conjugate puxitatug samrotecan may have a manageable safety profile consistent with similar antibody-drug conjugates and demonstrated initial efficacy in patients with heavily pretreated advanced or metastatic solid tumors, according to new findings presented by...
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical1 and endometrial cancers2 who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found...
In a long-term follow-up of Women’s Health Initiative (WHI) randomized trials reported in the Journal of Clinical Oncology, Rowan T. Chlebowski, MD, PhD, and colleagues identified risks of ovarian and endometrial cancers associated with the use of menopausal hormone therapy. Study Details The...
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
Researchers may have uncovered the germline mutational landscape of Chinese patients with ovarian cancer and identified an enriched RAD51D variant in these patients, according to a recent study published by Feng et al in JCO Global Oncology. The findings could serve as a critical reference for...
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
In a systemic analysis of global literature reported in The Lancet, Wei et al estimated the proportion of invasive cervical cancer cases caused by specific human papillomavirus (HPV) genotypes. Study Details A literature search through February 2024 was performed to identify studies reporting HPV...
Researchers have discovered that uterine serous carcinoma tumors in Black patients tend to express more aggressive and immunosuppressive features than tumors in White patients, according to a recent study published by Foley et al in Proceedings of the National Academy of Sciences. Uterine serous...
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...
Women whose fallopian tubes are removed during sterilization via laparoscopy may have only marginally more surgical complications compared with those whose tubes are cut during tubal occlusion, according to a recent study published by Strandell et al in The Lancet Regional Health–Europe. The...
Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...
In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...
As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...
I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...
The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...
In a Utah population–based cohort study reported in JAMA Network Open, Barnard et al found that women with ovarian endometriomas and/or deep-infiltrating endometriosis had a markedly increased risk of developing ovarian cancer. Those with such severe subtypes may represent an important population...
As reported in The New England Journal of Medicine by Ignace Vergote, MD, PhD, and colleagues, interim analysis of the phase III innovaTV 301 trial has shown improved overall survival and other efficacy outcomes with the antibody-drug conjugate tisotumab vedotin-tftv vs investigator’s choice of...